PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7:
A61K 35/00, C07H 21/02, 21/04, C12N 1/21,
1/15, 1/19, 5/14, 15/11, 15/63, 15/85, 15/86

A3 (11) International Publication Number:

WO 00/39136

(43) International Publication Date:

6 July 2000 (06.07.00)

(21) International Application Number:

PCT/US99/30452

(22) International Filing Date:

20 December 1999 (20.12.99)

(30) Priority Data:

60/113,804

23 December 1998 (23.12.98) US

(71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): YOUNG, Paul, E. [US/US]; 122 Beckwith Street, Gaithersburg, MD 20878 (US). RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Laytonsville, MD 20882 (US).

(74) Agents: KENNY, Joseph, J. et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(88) Date of publication of the international search report:

2 November 2000 (02.11.00)

(54) Title: HUMAN BRAINIAC-5

(57) Abstract

The present invention relates to novel Brainiac-5 polypeptides which are members of the Brainiac family. In particular, isolated nucleic acid molecules are provided encoding the human Brainiac-5 polypeptides. Brainiac-5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Brainiac-5 activities. Also provided are diagnostic methods for detecting immune and nervous system-related disorders and therapeutic methods for treating, preventing, and/or diagnosing immune and nervous system-related disorders.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
ΑU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
\mathbf{AZ}	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		-

International application No. PCT/US99/30452

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) :Please See Extra Sheet. US CL :Please See Extra Sheet.							
According t	o International Patent Classification (IPC) or to both national classification and IPC						
	DS SEARCHED						
	ocumentation searched (classification system followed by classification symbols)						
0.8. :	536/23.1, 23.4, 23.5, 24.31, 24.32, 24.33; 424/93.1, 435/69.1, 252.3, 254.2, 254.11, 25	4.11, 320.1, 325, 455					
Documentat	ion searched other than minimum documentation to the extent that such documents are included	in the fields searched					
Authors;	Authors; Young, Paul E., Ruben, Steven M.						
Electronic of	ata base consulted during the international search (name of data base and, where practicable	e, search terms used)					
Genbank,	CAPlus, Medline, WEST						
C. DOC	UMENTS CONSIDERED TO BE RELEVANT						
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.					
x	Genbank Database, Genbank, Accession No. AC005952, Lamerdin	1-4, 6-13 and 23					
	et al., Homo sapiens chromosome 19, cosmid F19847, complete						
Y, A	sequence, 08 November 1998, see in particular amino acids 188-199	5, 14-16 and 21					
	and 229-235 of SEQ ID NO:2 encoded by nucleic acids 28706-28741 and 28823-28843 of AC005952.						
	mid 20023 20043 01 /1C003/32.						
X	WO 98/21328 A2 (SAGAMI CHEMICAL RESEARCH CENTER)	1-16 and 23					
	22 May 1998(22.05.98), see in particular claim 1, p. 116-117, 205,						
Y, A	amino acids 77-83 and 188-199 of SEQ ID NO:2 in common with amino acids 182-188 and 293-304 of WO98/21328, SEQ ID NO:26	21					
	animo acids 182-188 and 293-304 of WO98/21328, SEQ 1D NO:20						
	ļ						
X Furth	er documents are listed in the continuation of Box C. See patent family annex.						
* Spe	cial categories of cited documents: "T" later document published after the inte- date and not in conflict with the appli						
	rument defining the general state of the art which is not considered the principle or theory underlying the						
	considered novel or cannot be considered to involve an inventive step						
*L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other							
considered to involve an inventive step when the document is "O" document referring to an oral disclosure, use, exhibition or other combined with one or more other such documents, such combination							
means being obvious to a person skilled in the art *P* document published prior to the international filing date but later than *&* document member of the same patent family the priority date claimed							
Date of the actual completion of the international search Date of mailing of the international search report							
11 JUL 2000							
Name and mailing address of the ISA/US Authorized of fife							
Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231							
Washington, D.C. 20231 Facsimile No.							
	SA/210 (second sheet) (July 1998)*	<u>(/</u> <u>'</u>					

International application No. PCT/US99/30452

C (Continua	tion). DOCUMENTS CONSIDERED TO BE RELEVANT	
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X Y, A	Genbank Database, Genbank, Accession No. H18701, Hillier et al., yn52d05.al Soares adult brain N2b5HB55Y Homo sapiens cDNA clone, 29 June 1995, see in particular amino acids 203-278 of SEQ ID NO:2 encoded by H18701 nucleic acids 3-230, nucleic acids 1-483 in common with nucleic acids 1-483 of H18701 and nucleic acids 785-977 of SEQ ID NO:1 in common with nucleic acids 181-373 of h18701.	1-4, 6-13 and 23 5, 14-16 and 21
X Y, A	Genbank Database, Genbank, Accession No. H38971, Hillier et al., yn84d06.s1 Soares adult brain N2b5HB55y Homo sapiens cDNA clone, 25 July 1995, see in particular nucleic acids 1-431 of SEQ ID NO:10 shared in common with nucleic acids 1-431 of H38971.	1-4, 6-13 and 23 5, 14-16 and 21

International application No. PCT/US99/30452

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)					
This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:					
1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:					
Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:					
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).					
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)					
This International Searching Authority found multiple inventions in this international application, as follows:					
Please See Extra Sheet.					
1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.					
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.					
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:					
4. X No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-16, 21 and 23					
Demands on Protect					
The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.					

International application No. PCT/US99/30452

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (7):

A61K 35/00; C07H 21/02, 21/04; C12N 1/21, 1/15, 1/19, 5/14, 15/11, 15/63, 15/85, 15/86,

A. CLASSIFICATION OF SUBJECT MATTER:

US CL:

536/23.1, 23.4, 23.5, 24.31, 24.32, 24.33; 424/93.1, 435/69.1, 252.3, 254.2, 254.11, 254.11, 320.1, 325, 455

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s)1-16, 21 and 23, drawn to the first technical feature, isolated nucleic acids.

Group II, claim(s) 17-18, and 22, drawn to the second technical feature, isolated polypeptides.

Group III, claim(s) 19, drawn to the third technical feature, isolated antibodies.

The inventions listed as Groups I-III do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The special technical features differ in structure and function, in particular Group I is composed of nucleic acids capable of hybridization, Group II is composed of amino acids capable of dimerization and Group III is composed of immunoglobulins capable of an immune reaction.